Teclistamab for R/R myeloma

preview_player
Показать описание
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses a Phase I study of teclistamab, a humanized b-cell maturation antigen (BCMA), CD3 bispecific antibody, for the treatment of relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Maria-Victoria Mateos
  3. Institution: University of Salamanca
  4. Event: VJVirtual
  5. Event: EHA 2020
  6. Format: Interview
Рекомендации по теме
The recent FDA 0:01:00

The recent FDA approval of teclistamab for R/R multiple myeloma

Teclistamab for R/R 0:05:38

Teclistamab for R/R myeloma

FDA approval of 0:00:45

FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies

The value of 0:01:45

The value of teclistamab in R/R myeloma & strategies to mitigate toxicities

Real-world outcomes of 0:01:43

Real-world outcomes of teclistamab for R/R multiple myeloma

2-year follow-up of 0:00:46

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma

MajesTEC-2 update: teclistamab 0:00:45

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myeloma

Update on Phase 0:03:45

Update on Phase I trial of teclistamab in R/R myeloma

Dr Garfall on 0:01:15

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

Safety and efficacy 0:01:43

Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma

Clinical benefit of 0:01:14

Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma

RedirecTT-1 results: teclistamab 0:05:54

RedirecTT-1 results: teclistamab + talquetamab in R/R multiple myeloma

Real-world outcomes of 0:01:50

Real-world outcomes of teclistamab treatment in R/R multiple myeloma

MajesTEC-1: update on 0:03:05

MajesTEC-1: update on RP2D of teclistamab in R/R myeloma

Updated data on 0:03:05

Updated data on subcutaneous teclistamab in R/R myeloma

Approval of teclistamab 0:02:04

Approval of teclistamab in triple-class refractory multiple myeloma

Real-world dose de-escalation 0:02:41

Real-world dose de-escalation of teclistamab in patients with R/R myeloma

Real-world study determining 0:04:13

Real-world study determining the safety and efficacy of teclistamab in R/R multiple myeloma

Bispecific BCMA-CD3 antibody 0:01:29

Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM

Evaluating Teclistamab in 0:08:12

Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

MajesTEC‐1 update: rates 0:01:53

MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab

Evaluating teclistamab step-up 0:03:46

Evaluating teclistamab step-up dosing & dose de-escalation in R/R myeloma in the real-world sett...

Efficacy of Teclistimab 0:05:41

Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myeloma

Teclistamab Approval For 0:02:33

Teclistamab Approval For Multiple Myeloma Treatment | Ross Firestone, MD, PhD | ASCO 2023